Omrix now part of Johnson & Johnson

By Lisa Kerner

Charlotte, N.C., Dec. 30 - Johnson & Johnson completed its $438 million acquisition of Omrix Biopharmaceuticals, Inc., it was announced on Tuesday.

Omrix, a New York-based biopharmaceutical company, will operate as a standalone entity through Johnson & Johnson's Ethicon, Inc., which provides suture, mesh, hemostats and other products for surgical procedures, a Johnson & Johnson news release said.

Johnson & Johnson, a New Brunswick, N.J.-based pharmaceutical company, completed its $25-per-share tender offer for Omrix on Dec. 26.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.